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This population-based study aimed to fill the knowledge gap on Human Papillomavirus
(HPV) prevalence and associated sociodemographic risk factors of the general population
in the North Tongu District, Ghana. These results are needed to guide cervical cancer pre-
vention efforts, as the leading type of female cancers.
Methods
A cross-sectional study including 2002 women in the North Tongu District, Ghana investi-
gated HPV prevalence and associated sociodemographic risk factors. Women were
recruited by geographical distribution through the local community-based health system and
samples collected using a self-sampling device. For HPV genotyping BSGP5+/6+-PCR with
Luminex-MPG readout was used. Multivariate logistic regression analyzed sociodemo-
graphic risk factors for HPV positivity.
Results
Of 2002 self-collected samples, 1943 were eligible, contained sufficient DNA and provided
valid HPV genotyping results. Prevalence of single high risk HPV types was 32.3% and of
multiple high risk types 9.7%. The five most common detected HPV types were HPV16
(7.4%; 95%CI: 6.3–8.7), HPV52 (7.2%; 95%CI: 6.1–8.5), HPV35 (4.8%; 95%CI: 3.9–5.8),
HPV59 (4.7%; 95%CI: 3.8–5.8), HPV56 (3.9%; 95%CI: 3.1–4.8). Highest prevalence was
observed among women aged 18–24 years, while age 25–54 years was inversely associ-
ated with high risk HPV positivity in multivariate analysis. Sociodemographic risk factors
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identified were i) having any sexual partner, ii) more partners increased the odds for high
risk HPV positivity, iii) independently from this marital status, in particular not being married.
Discussion & conclusion
Most importantly, the high risk HPV prevalence detected from this study is higher than esti-
mates reported for Western Africa. This needs be considered, when deciding on the cervical
cancer screening algorithms introduced on a wider scale. Follow-up and triage, depending
on the methods chosen, can easily overburden the health system. Self-sampling worked
well and provided adequate samples for HPV-based screening. Women with increasing
number of sexual partners and not being married were found to have higher odds of being
high risk HPV positive, therefore could be a higher prioritized screening target group.
Introduction
Global situation HPV & cervical cancer
Cervical cancer is the 4th most common cancer among women in the world leading to about
528.000 registered new cancer cases and 266.000 cervical cancer deaths annually [1]. About
99% of cervical cancer cases are caused by persistent infection with Human Papillomaviruses
(HPV) [2] and genotypes HPV16 and HPV18 cause approx. 70% of the global cervical cancer
cases [3]. Regional differences exist for the HPV genotype distribution in cervical cancer. In
Sub-Saharan Africa HPV16, 18, 45, 35 and 33 were identified as the most common types [4],
while globally HPV16, 18, 45, 33 and 31 are most common in the respective order [3]. With
different risks for and time to cancer progression as well as possible protection from HPV vac-
cination, genotype prevalence and distribution are important factors to investigate in each
world region.
Low-middle income countries (LMIC) carry the greatest global burden of cervical cancer
with about 85% of incident cases and 87% of annual deaths occurring there [1]. Reasons for
this are late presentation at the health facilities [5], poorly developed health systems, lack of
financial and technical resources as well as human capacity to diagnose and treat cervical can-
cer, and often also lack of awareness [6]. This high rate of cervical cancer incidence is projected
to increase by 90% until 2030 when considering the current increase in incidence as well as
aging and population growth [7]. Factors such as the increasing number of HIV-positive
patients further contribute to this projection [7]. While HPV vaccines are available and pro-
vide effective primary prevention, their accessibility in LMICs is still limited mostly to initia-
tives by the Global Alliance for Vaccines and Immunization (GAVI). Furthermore, the
available vaccines do not cover all high risk HPV types and therefore the need for simple,
affordable and acceptable secondary prevention remains inevitable. A review of policy docu-
ments and interviews with key stakeholders from Tanzania, Kenya and Uganda shows that
although the advantage of HPV testing for cervical cancer screening is understood, screening
remains rare and is often offered to women outside the recommended age range. Programs
are underfunded, resulting in low coverage and insufficient quality [8].
In Ghana cervical cancer is the 2nd most common female cancer among women at the age
of 15 to 44 years and the 2nd leading cause of cancer deaths [9]. With a crude incidence rate of
18.6 per 100.000 annually, cervical cancer is even more common in Ghana compared to the
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Western Africa region with 16.8 per 100.000 [1, 9]. At the Korle Bu Teaching Hospital Accra
57.8% of the women presenting with gynecological cancer had cervical cancer [10].
Despite this high burden of disease little is known about the prevalence of HPV infection
and its risk factors in the general population of Ghana. Studies investigating this are very rare
and limited to small studies (n<230) or specialized populations (e.g. referral population, cervi-
cal cancer patients, pregnant women). Prevalence rates stated are for example 10.7% among 75
women attending the gynecology outpatient clinic in Accra [11], or 42% and 76.6% among
100 HIV negative and 107 HIV positive women from Kumasi, respectively [12]. A study
among pregnant women from the Western Region of Ghana detected 13.9% of the women
to be high risk HPV positive [13]. Few studies focused on the HPV genotype distribution
among cervical cancer patients. The Pathology Department at the University of Ghana found
the most common HPV types among 230 cervical cancer patients to be HPV18 (47.4%),
HPV59 (42.2%), HPV45 (37.4%) and HPV16 (9.0%) with 52.2% having multiple HPV types
[14]. Thus, no large population-based study depicting the HPV prevalence has been published
from Ghana to date.
The ACCESSING study
ACCESSING is an acronym for “Adequate Cervical cancer Capacity building, Education and
Screening by new Scientific INstruments in Ghana” and a program funded by the Deutsche
Gesellschaft fu¨r Internationale Zusammenarbeit (GIZ) and the German Rotary Voluntary
Doctors (GRVD). The program was conducted during a hospital partnership in collaboration
between the Catholic Hospital Battor in the Volta Region, Ghana, and the Charite´—Universi-
ta¨tsmedizin Berlin, Clinic for Gynecology, Germany. The aims of this program were to assess
the HPV and STI prevalence with a cross-sectional study design in the general population, to
evaluate a potential screening algorithm for cervical cancer screening on its feasibility, and to
build the capacity to independently and autonomously introduce cervical cancer screening.
The program was conducted from October 2013 until February 2017 including two pilot stud-
ies with 250 and 150 women screened at the Catholic Hospital Battor, respectively, and a main
study with 2002 women screened from the rural and urban communities in the North Tongu
District.
This manuscript presents the results from the ACCESSING main study investigating HPV
prevalence, genotype distribution, and the sociodemographic risk factors associated with high
risk HPV positivity. This shall help decision makers to identify adequate cervical cancer
screening methods and potentially prioritized risk groups for screening.
Methods
Study population
This evaluation of the ACCESSING program is a cross-sectional study conducted in the North
Tongu District, Ghana in a collaboration of the Catholic Hospital Battor, Ghana and the Char-
ite´—Universita¨tsmedizin Berlin, Germany. Women in the age of 18 to 65 years without a his-
tory of cervical cancer and who were not pregnant were recruited.
Sample size calculation was based on a HPV prevalence estimate of 21.3% and the objective
to identify a clinically relevant difference of 2.5% to this suggested prevalence [15]. Adjusting
for a potential loss to follow-up, loss of sample material or unusable samples of between 5–6%
and at a 5% significance level with 80% statistical power, the sample size needed was 2003 [16].
Thus a sample size of 2000 women was proposed to be sufficient to detect a clinically impor-
tant difference.
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Ethical clearance for this study was given by the Ghana Health Service Ethical Review Com-
mittee (Ref. No. GHD-ERC: 05/05/13) in October 2013. Signed/thumb-printed written/trans-
lated informed consent was obtained from all women participating in the screening.
Sample collection
The number of women included in each village within the North Tongu District was defined
based on the population size reported during the latest Population Census from 2010 and
adjusted to a sample size of 2000 study participants [17]. Recruitment of study participants
was conducted by Community Health Workers (CHW), as part of the Ghana Health Service
Community-based Health Planning and Services (CHPS), who are based in the respective vil-
lages, on a door-to-door and first-come-first-serve basis.
The samples were collected using an approved (Ghana FDA) self-sampling device, namely
the Evalyn brush (Rovers Medical Devices, Oss, The Netherlands). Evalyn Brush samples were
self-collected or collected with assistance from a CHW according to manufacturer’s instruc-
tions and stored dry and at ambient temperature for a maximum time period of 7 days until
arrival in the laboratory of the Catholic Hospital Battor, Ghana. Every woman screened filled
out a questionnaire asking for general demographic data (e.g. age, education, and income level
per month) as well as specific risk factors such as age at first intercourse, number of sexual
partners, etc. (see supporting information S1 File for the questionnaire).
Sample processing & HPV genotyping
The brush head was removed from the self-sampling applicator into a 2 ml Eppendorf tube
and 1 ml of PreservCyt solution was added and vortexed vigorously for about 1 min. After
incubation overnight at room temperature brushes were vortexed again and then removed.
100 μl from this cell suspension were aliquoted and stored at -20˚C for DNA extraction at the
Laboratory for Gynecologic Tumor Immunology, Clinic for Gynecology, Charite´ Universita¨ts-
medizin Berlin.
For DNA extraction, the Maxwell 16 LEV Blood DNA Kit (Promega GmbH, Mannheim,
Germany) was used according to manufacturer’s instructions. DNA was eluted into 60 μl of
elution buffer and stored at -20˚C until further used.
Genotyping of mucosal HPV was done by BSGP5+/6+ PCR followed by Luminex-MPG
read-out according to Schmitt et al. 2008 [18] detecting the genotypes 6, 11, 16, 18, 26, 31, 33,
35, 39, 42, 43, 45, 51, 52, 53, 54, 56, 57, 58, 59, 66, 68a, 68b, 70, 72, 73, 82 and 90 at Charite´—
Universita¨tsmedizin Berlin, Germany. Clinical performance of this test has been validated and
considered useful for HPV-based cervical cancer screening [19]. Results were considered valid
if sufficient DNA was present, indicated by a Luminex measured Median Fluorescent Intensity
(MFI) of 200 or more for ß-globin, which was used as a proxy for cellular material. The MFI is
interpreted qualitatively, indicating if a sample is positive or negative for the respective HPV
type, but not used for quantitative information on the viral load of samples.
According to WHO monograph classification HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, and 59 were considered as high risk HPV genotypes. HPV66 and 68a and 68b were
defined as probable, HPV26, 53, 73, and 82 as potential high risk and the HPV types 6, 11, 42,
43, 54, 57, 70, 72, 90 as low risk types [20].
Clinical follow-up
Women who tested positive for high risk HPV were recalled to the clinic for cytology and
upon abnormal cytology result called again for colposcopy. Based on the diagnosis by the
treating gynecologist treatment, such as loop electrosurgical excision procedure (LEEP) or
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hysterectomy, was provided. Cytological examination was done at the Department of Pathol-
ogy, University of Cape Coast, Ghana. HPV testing as well as any clinical follow-up required
were provided free of charge for the study participants.
Statistical analysis
Statistical analysis of categorical data was done using high risk HPV positivity as the dependent
variable. Univariate and multivariate logistical regression analysis was used to identify poten-
tial sociodemographic risk factors for high risk HPV positivity. Variables for multivariate
logistic regression were chosen based on their association resulting from univariate analysis as
well as from sociodemographic risk factors reported in the literature. The multivariate model
was built using forward stepwise selection and the likelihood ratio test to compare the fit of the
models. The unadjusted odds ratio (OR), adjusted odds ratio (AOR), 95% confidence intervals
(95%CI) and p-values from univariate and multivariate logistic regression were reported as a
measure of association. All reported p-values were 2-sided with a significance level of 0.05. For
statistical analysis STATA version 15 (StataCorp LLC, College Station, Texas, USA) was used.
Results
From a total of 2002 women samples with a self-sampling brush were collected through the
CHW system in the North Tongu District within 5 weeks. Two samples did not reach the labo-
ratory, 18 were excluded from this analysis because they were not within the age range of 18–
65 years and an additional 39 samples were excluded due to insufficient DNA present in the
sample for HPV testing. Hence a total of 1943 samples were included in the HPV and risk fac-
tor analysis (Fig 1). Among the 2002 samples tested this represents sufficient DNA for 98% of
samples.
Sociodemographic description
The distribution of sociodemographic characteristics is summarized in Table 1 with a few
details described here: The average age of the women tested was 32 years of age. The majority
of women completed Junior High School or higher (59.8%) and about half of the women had a
monthly income of less than 100 Ghana Cedi (GHS), which calculated to approx. US $ 25 per
month (in August 2015). The most common occupations were trading and farming and about
9.5% were students or doing an apprenticeship. Many women recruited were married (42.2%)
and had 1–2 children (38.0%), ranging to up to 13 children. The majority did not use any con-
traceptive (66.0%) and had 2–3 sexual partners. Almost half (48.0%) of the women were
between 15–18 years when they had their first sexual intercourse.
HPV prevalence results from the North Tongu District, Ghana
Among the 1943 samples left for analysis, high risk HPV was detected in 32.3% (95%CI: 30.2–
34.5) and 9.7% (95%CI: 8.4–11.1) were positive for multiple high risk HPV types. On average
women with multiple high risk types had 1.4 high risk types detected (range: 1–7 high risk
types). 18.4% (95%CI: 17.7–20.2) were positive for low risk HPV as single or multiple infection
and 53.5% (95%CI: 51.3–55.8) HPV negative. Among women aged 30–49 years, the WHO rec-
ommended screening age, high risk HPV prevalence was 27.3% (95%CI: 24.3–30.5). Women
high risk HPV positive were invited for clinical follow up free of charge. This was structured in
cytology and based on indication colposcopy, LEEP and potentially hysterectomy. Results of
clinical follow up are presented in the supporting information S1 Fig.
HPV prevalence and risk factors to guide cervical cancer screening in Ghana
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The five most prevalent high risk HPV types were HPV16 (7.4%; 95% CI: 6.3–8.7), HPV52
(7.2%; 95% CI: 6.1–8.5), HPV35 (4.8%; 95%CI: 3.9–5.8), HPV59 (4.7% 95% CI: 3.8–5.8) and
HPV56 (3.9%; 95% CI: 3.1–4.8) (Table 2). HPV66, as a probable high risk type was detected in
4.3% (95% CI: 3.5–5.3) of the women. The most common low risk type detected was HPV42
(7.1%; 95% CI: 6.0–8.3).
The age-specific HPV prevalence is presented in Fig 2 and was highest among women
younger than 25 years (41.7%; 95% CI: 37.5–45.9). With increasing age, prevalence decreases
up to 54 years and then increases again in the oldest age group of 55–65 years. Lowest preva-
lence is seen in the age group 45–54 years with 25.1% (95% CI: 19.3–31.7).
Risk factors associated with high risk HPV positivity
Univariate analysis suggests high evidence for decreasing odds ratio (OR) of high risk HPV
positivity for women with the following sociodemographic factors (Table 3). Women at older
age had lower ORs for high risk HPV infection compared to those of younger age. Further-
more, women who work as farmers (OR: 0.4; 95%CI: 0.3–0.6; p-value: <0.001), teacher (OR:
0.5, 95%CI: 0.3–0.8; p-value: 0.010), traders (OR: 0.6; 95%CI: 0.4–0.8; p-value: 0.001) or in the
health care sector (OR: 0.4; 95%CI: 0.2–0.9; p-value: 0.032) were associated with a decreased
OR for infection compared to students or women doing an apprenticeship. The OR increased
for women who completed primary (OR: 1.5; 95%CI: 1.1–2.0; p-value: 0.016) or secondary
school (OR: 1.7; 95%CI: 1.2–2.5; p-value: 0.002) in comparison to those without any
Fig 1. Flow chart of ACCESSING main HPV screening study in 2014.
https://doi.org/10.1371/journal.pone.0218762.g001
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Table 1. Sociodemographic and behavioral characteristics of eligible study participants (n = 1982).











Junior High School 793 40.0
Secondary 254 12.8
Post Secondary 73 3.7
Post Graduate 65 3.3
missing data 15 0.8
Income level per month
<100 GH¢ 989 49.9
100–250 GH¢ 329 16.6
251–500 GH¢ 106 5.4
>500 GH¢ 109 5.5









Unemployed/House wife/Retired 129 6.5
Food vendor 46 2.3
Office Employee 30 1.5
Cleaner 9 0.5
missing data 116 5.9
Marital Status
Single 178 9.0
Have a steady partner 395 19.9




missing data 1 0.1
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educational degree. No such association was seen for women who completed Junior High
School. High evidence for increasing ORs of high risk HPV positivity was seen among women
who are single (OR: 2.6; 95%CI: 1.8–3.6; p-value:<0.001), or are not married—including
those who have a steady partner (OR: 2.6; 95%CI: 2.0–3.4; p-value: <0.001), live with someone
(OR: 1.5, 95%CI: 1.2–1.9; p-value: 0.003) or are divorced but not widowed (OR: 1.8; 95%CI:
1.1–2.9; p-value: 0.014), compared to married women. The number of children a woman had
steadily decreased her OR of being high risk HPV positive. Other factors such as age at first
sexual intercourse, the use of contraceptives and income level did not show high evidence for
an association with HPV positivity in univariate analysis.
After multivariate logistical regression only the factors age, marital status and number of
sexual partners appeared to have a high association for infection (Table 4). Here, as mentioned
above younger age had a higher OR for infection. Being single (AOR: 2.6; 95%CI: 1.8–3.8; p-
value:<0.001), having a steady partner but not living together (AOR: 2.2; 95%CI: 1.6–2.9; p-
value:<0.001) and being divorced (AOR: 1.9; 95%CI: 1.2–3.0; p-value: 0.011) were highly
Table 1. (Continued)
Sociodemographic characteristics n Prevalence in %







missing data 5 0.3




















missing data 10 0.5
Abbreviations: GH¢—Ghana Cedi (100 GH¢ ~ 25US$, exchange rate in August 2015); IUCD—Intrauterine
contraceptive device
https://doi.org/10.1371/journal.pone.0218762.t001
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associated with high risk HPV positivity. Living with someone but not being married (AOR:
1.3; 95%CI: 1.0–1.7; p-value: 0.047) was also associated with infection. The more sexual part-
ners a woman had the higher the ORs for infections were (e.g. >3 partners AOR: 5.0; 95%CI:
1.7–14.6; p-value: 0.004). Interestingly, there was already a high association for infection with
the first sexual partner (AOR: 3.3; 95%CI: 1.1–9.3; p-value: 0.027).
Table 2. Prevalence of HPV by genotype among eligible women (n = 1943).
HPV Type positivity Infections positive (n) (%) 95% CI
High risk HPV
16 144 7.4 6.3–8.7
18 72 3.8 2.9–4.6
31 47 2.4 1.8–3.2
33 15 0.8 0.4–1.3
35 93 4.8 3.9–5.8
39 40 2.1 1.5–2.8
45 63 3.2 2.5–4.1
51 58 3.0 2.3–3.8
52 140 7.2 6.1–8.5
56 75 3.9 3.1–4.8
58 45 2.3 1.7–3.1
59 92 4.7 3.8–5.8
Probable high risk HPV
66 84 4.3 3.5–5.3
68a 28 1.4 1.0–2.1
68b 47 2.4 1.8–3.2
Potential high risk HPV
26 7 0.4 0.1–0.7
53 72 3.7 2.9–4.6
73 24 1.2 0.8–1.8
82 59 3.0 2.3–3.9
Low risk HPV
6 51 2.6 2.0–3.4
11 12 0.6 0.3–1.1
42 137 7.1 6.0–8.3
43 23 1.2 0.8–1.8
54 50 2.6 1.9–3.4
57 1 0.1 <0.1–0.3
70 45 2.3 1.7–3.1
72 12 0.6 0.3–1.1
90 87 4.5 3.6–5.5
HPV positivity women positive (n) (%) 95% CI
HPV negative 1040 53.5 51.3–55.8
High risk HPV+ 628 32.3 30.2–34.5
Single high risk HPV+ 440 22.6 20.8–24.6
Multiple high risk HPV+ 188 9.7 8.4–11.1
High risk AND probable HPV+ 697 35.9 33.7–38.1
High risk AND probable AND potential HPV+ 750 38.6 36.4–40.8
Low risk HPV+ 405 18.4 17.7–20.2
Abbreviations: OR—odds ratio; CI—Confidence interval; HPV—Human Papillomavirus
https://doi.org/10.1371/journal.pone.0218762.t002
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Discussion
Sample collection via self-sampling worked exceptionally well in this study. The integration of
recruitment and sampling in the responsibilities of CHW system allowed simultaneous screen-
ing across the District within only 5 weeks. With 98% of the samples providing valid HPV
genotyping results, this sampling method should be considered for large-scale screening pro-
grams, especially for widespread communities.
HPV prevalence in Ghana
The results of this cross-sectional HPV prevalence study show an exceptionally high preva-
lence of the high risk HPV genotypes of 32.3%. This is a 52% increase compared to the initially
expected prevalence of 21.3%, which had been used as an estimate for Western Africa in the
sample size calculation [15]. Even among women aged 30–49 years, the WHO recommended
screening age, high risk HPV prevalence is high and above the estimate for Western Africa
with 27.3%.
Looking at some of the other scarce studies conducted among the general population in
Ghana, a prevalence of 10.7% was found among 75 women (mean age: 33.3 years) attending
the gynecology outpatient clinic in Accra [11], or of 42% among 100 HIV negative women
(mean age: 40.9 years) attending the outpatient department of a referral hospital in Kumasi
[12]. Schulze et al. reported a prevalence of 13.9% for high risk HPV among pregnant women
in Eikwe, Southwest Ghana [13]. Although not directly reflecting the situation in Ghana, the
extensive meta-analysis including 1 million women across 5 continents estimates the preva-
lence for Western Africa at 19.6% after adjusting for various factors such as geographical sub-
region, mean age of women, HPV testing method etc. [21]. A study from the neighboring
country Burkina Faso reports a prevalence similar to our findings of 34.4% among women
aged 35.5 years recruited among visitors of an urban medical center [22]. One could hypothe-
size that women referred to and recruited from a medical center possibly with characteristic
symptoms have a higher risk of being HPV positive, may rather be considered a referral
Fig 2. High-risk HPV prevalence by age group.
https://doi.org/10.1371/journal.pone.0218762.g002
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Table 3. Univariate logistic regression analysis of potential risk factors for high risk HPV positivity.
Characteristic Total High risk HPV+ OR 95% CI p-value
Age <0.001
18–24 545 227 Ref.
25–34 727 218 0.6 0.5–0.8 <0.001
35–44 392 110 0.6 0.4–0.7 <0.001
45–54 203 51 0.5 0.3–0.7 <0.001
55–65 76 22 0.6 0.3–1.0 0.036
Education
None 335 91 Ref.
Primary 427 151 1.5 1.1–2.0 0.016
Junior High School 784 248 1.2 0.9–1.7 0.137
Secondary 248 97 1.7 1.2–2.5 0.002
Post Secondary 72 24 1.3 0.8–2.3 0.293
Post Graduate 62 15 0.9 0.5–1.6 0.627
Income level per month 0.019
<100 GH¢ 976 317 Ref.
100–250 GH¢ 321 87 0.8 0.6–1.0 0.072
251–500 GH¢ 100 23 0.6 0.4–1.0 0.054
>500 GH¢ 106 28 0.8 0.5–1.2 0.204
Occupation
Apprentice/Student 183 80 Ref.
Farmer 487 125 0.4 0.3–0.6 <0.001
Hairdressing 82 29 0.7 0.4–1.2 0.203
Health care 34 8 0.4 0.2–0.9 0.032
Seamstress 110 44 0.9 0.5–1.4 0.533
Teacher 73 19 0.5 0.3–0.8 0.010
Trader 654 201 0.6 0.4–0.8 0.001
Unemployed/House wife/Retired 127 47 0.8 0.5–1.2 0.238
Food vendor 43 15 0.7 0.3–1.4 0.293
Office 29 10 0.7 0.3–1.5 0.352
Cleaner 9 2 0.4 0.1–1.8 0.220
Marital Status
Single 174 77 2.6 1.8–3.6 <0.001
Have a steady partner 387 174 2.6 2.0–3.4 <0.001
Living with someone (unmarried) 415 132 1.5 1.2–1.9 0.003
Married 825 196 Ref.
Divorced 83 30 1.8 1.1–2.9 0.014
Widowed 58 19 1.6 0.9–2.8 0.125
Number of sexual partners 0.003
None 23 5 Ref.
1 750 224 1.5 0.6–4.2 0.404
2–3 938 306 1.7 0.6–4.7 0.276
>3 208 85 2.5 0.9–7.0 0.082
Number of children <0.001
None 342 148 Ref.
1–2 745 250 0.7 0.5–0.9 0.002
3–4 476 138 0.5 0.4–0.7 <0.001
5–6 240 61 0.5 0.3–0.6 <0.001
>6 135 29 0.4 0.2–0.6 <0.001
(Continued)
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Table 3. (Continued)
Characteristic Total High risk HPV+ OR 95% CI p-value
Age at first intercourse 0.045
<15 64 26 Ref.
15–18 935 319 0.8 0.5–1.3 0.291
19–22 608 188 0.7 0.4–1.1 0.115
23–26 103 31 0.6 0.3–1.2 0.164
>26 24 6 0.5 0.2–1.4 0.179
Contraceptive Use
None 1278 397 Ref.
Injectable 341 123 1.3 1.0–1.6 0.079
Pill 138 45 1.1 0.7–1.6 0.710
Norplant/Jadelle 81 33 1.5 1.0–2.4 0.071
Condom 65 19 0.9 0.5–1.6 0.755
Abstinence 24 7 0.9 0.4–2.2 0.842
IUCD 4 0
Other 8 3 1.3 0.3–5.6 0.696
Current smoking
Yes 17 5 0.9 0.3–2.5 0.797
No 1917 620 Ref.
Usage of herbal vaginal preparation
Yes 246 74 0.9 0.7–1.2 0.422
No 1691 552 Ref.
Abbreviations: OR—odds ratio; CI—Confidence interval; HPV—Human Papillomavirus; GHC—Ghana Cedi; IUCD—Intrauterine Contraceptive Device
https://doi.org/10.1371/journal.pone.0218762.t003
Table 4. Risk factors associated with high risk HPV positivity from multivariate analysis.
High risk HPV positivity Multiple high risk HPV type positivity
Characteristic Adjusted OR 95% CI p-value Adjusted OR 95% CI p-value
Age
18–24 Ref. Ref.
25–34 0.7 0.5–0.8 0.001 0.7 0.5–1.0 0.083
35–44 0.7 0.5–0.9 0.013 0.4 0.2–0.7 0.001
45–54 0.6 0.4–0.8 0.005 0.7 0.4–1.3 0.243
55–65 0.7 0.4–1.2 0.172 0.6 0.3–1.6 0.331
Marital Status
Single 2.6 1.8–3.8 <0.001 2.5 1.4–4.4 0.002
Have a steady partner 2.2 1.6–2.9 <0.001 2.5 1.6–3.9 <0.001
Living with someone (unmarried) 1.3 1.0–1.7 0.047 1.8 1.1–2.8 0.015
Married Ref. Ref.
Divorced 1.9 1.2–3.0 0.011 3.5 1.8–7.0 <0.001
Widowed 1.6 0.9–2.9 0.135 1.4 0.5–4.1 0.579
Number of sexual partners
None Ref. -
1 3.3 1.1–9.3 0.027 Ref.
2–3 3.7 1.3–10.4 0.016 1.1 0.8–1.5 0.675
>3 5.0 1.7–14.6 0.004 1.7 1.1–2.8 0.028
Abbreviations: OR—odds ratio; CI—Confidence interval
https://doi.org/10.1371/journal.pone.0218762.t004
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population and that this reported prevalence is therefore an overestimation. However, our
findings support such high prevalence also to be seen among the general population. This is
further supported by a different study conducted in Western Burkina Faso finding a preva-
lence of 38.3% [23] and a prevalence of 33.2% reported from Benin [24]. Other studies report
prevalence or type distribution among selected populations, such as women with cervical
lesions or even cervical cancer or HIV-positive women, which cannot be compared to this
prevalence among the general population. Ghana has an overall low HIV rate of 1.5% and
even though the Volta Region with 2.7% has the highest reported HIV prevalence within the
country, it is still low compared to other Sub-Saharan African countries and may not explain
the high prevalence found [25]. While the prevalence seen here may not be representative for
the prevalence in Western Africa or even other regions in Ghana, given the large sample size it
is a valid representation of the prevalence in the North Tongu District of Ghana, which is
higher than so far reported and expected.
Nevertheless, the majority of women (65.4%) recruited for this study was at the age of 18–
34 years with a prevalence of 35.0% for this age group. Looking at the age distribution of the
population living in North Tongu district from the 2010 Population and Housing Census, the
age group 20–34 years comprises about 51.0% among the 20–64 years old women (similar to
the age range meeting the study inclusion criteria) of the North Tongu population and is
hence overrepresented among the women recruited for this study. On the other hand the older
age group (45–65 years; 34.6% of the study participants) comprises 48.9% among 20–64 years
old in North Tongu women’s population and is therefore underrepresented here. Since the
peak of HPV infection is expected among women aged�25 years [26], this could cause an
overestimation of the actual prevalence among the general population in the North Tongu
District.
Additionally, it has been described that although the accuracy of HPV testing from self-col-
lected samples compared to physician-obtained samples is similar, there is a tendency of more
HPV types being detected in self-collected samples from the cervicovaginal compartment as
compared to physician-collected cervical-targeted sampling [27–30]. This could also lead to an
overestimation of the prevalence described here, compared to commonly reported cervical
HPV prevalence. Another methodological factor that could influence the reported prevalence
of various studies is the sensitivity of testing methods for HPV detection. Different HPV detec-
tion methods have slightly different sensitivities and would therefore over- or underestimate
the true HPV prevalence in the population.
HPV type distribution
The five most prevalent high risk HPV types found in this study are 16, 52, 35, 59 and 56, in
descending order, known to contribute to a total of 59.4% of cervical cancer cases in the Afri-
can Region, as defined by WHO [31]. The types 35, 56 and 59 are not included in any HPV
vaccine, but in this study contribute to a prevalence of 12.4% (some women are positive for
two of the mentioned types). Looking at the prevalence of these types in invasive cervical can-
cer, as reported for Western Africa, all three types are among the top 10 cervical cancer causing
HPV types, being prevalent in 16.4% of cancers, with HPV59 alone contributing almost 10%
[31]. The prevalence of these non-vaccine covered HPV types shows that certain HPV vaccines
may not be as effective in this region as compared to other regions of the world. The preva-
lence of distinct HPV genotypes varies between world regions and also in the African conti-
nent. Reasons could be e.g. the local prevalence of HIV that leads to more multiple and
persistent infections by other genotypes than HPV16. Data on prevalence from sufficiently
large studies are sparse for Western Africa and a direct comparison cannot be drawn due to
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use of different HPV genotyping tests. However, HPV35 (rank 4–5) and 39 (rank 10) have
shown a dominating proportion in other African regions [31].
Multiple HPV infections
9.7% of the women in this investigated population had multiple high risk HPV infections.
Multiple high risk HPV infections are often reported among HIV positive persons [32–34].
However, it may not fully explain the results seen from the population recruited for this study.
As mentioned above, Ghana has an overall low HIV rate, which therefore may not be the only
contributor to the high prevalence of multiple high risk infections [25]. Another aspect
described to be associated with high prevalence of multiple infections is high promiscuity
among sex workers [35]. Among the women recruited 10.6% had more than 3 sexual partners
and the mean number of partners is 2.1. The number of sexual partners was associated with
single high risk infection, but also with multiple high risk HPV infection from multivariable
regression analysis of this study (Table 4). Multiple type positivity is an important factor to
investigate, as it increases somebodies risk of infection with additional HPV types and is under
debate to also reduce their risk to clear prevalent types, meaning prevalent types persist longer
[36]. It also reduces the survival of cervical cancer patients and has a higher rate of distant
tumor recurrences [37].
Risk factors for HPV positivity
Based on the self-reported answers provided to the questionnaires several risk factors have
been investigated and shown to be associated with high risk HPV infection. Knowledge of
these risk factors is of great importance to target women at highest risk of infection with
screening programs, especially in countries with limited resources for screening. Three risk
factors remained associated with high risk HPV infection after multivariable regression analy-
sis: Age, relationship status, and number of sexual partners.
Transmission of genital HPV and hence infection occurs with the onset of sexual activity
and HPV infection has been described to peak among younger women aged�25 years [26].
This is supported by the results from this study with the highest HPV prevalence of 41.7%
found among women younger than 25 years. The multivariate analysis further confirmed this,
showing the lowest ORs among older women compared to women younger than 25 years.
Being single or divorced was highly associated with infection compared to being married.
Surprisingly, having a steady partner and living with someone but not being married was also
associated with infection, even after adjusting for age and the number of sexual partners. This
might be due to ambivalent interpretation of these two categories by the study participants.
The questionnaires were filled out under supervision of the CHW and that might have influ-
enced the answers given. Possibly different interpretation of relationship length influenced the
category of “having a steady partner”. Other studies reported that being in a relationship for 12
months or longer is protective for infection, indicating that the duration of a relationship
seems to be an important factor [38]. In the literature early age at marriage is also described to
be associated with HPV infection [39], which is a factor that was not asked for. Beside from
this, the number of sexual partners in a lifetime is one of the most important factors associated
with HPV positivity. Various studies could show, similarly to our findings, that an increasing
number of sexual partners also increase the OR of being high risk HPV positive [39–42].
While other studies mostly focus on the number of sexual partners as a risk factor and rarely
investigate the relationship status, interestingly we see both factors to be independent risk fac-
tors. Our results show an association between relationship status and the number of sexual
partners, but when including both in the multivariable regression analysis, both remain
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independently highly associated with HPV infection. This means that both are independent
risk factors despite their association. This has not yet been investigated in other studies.
Other studies found lower levels of formal education to be associated with infection
[43]. In our population we can only partially confirm this, since we found primary and sec-
ondary education to be associated with higher risk of infection, however we did not see a dif-
ference in association between no or post-graduate education. Educational level was also not
associated anymore with high risk infection in the multivariate analysis after adjustment.
Also, cigarette smoking has been reported to be associated with HPV infection [41]. Since
only about 1% of our study participants indicated to smoke we could not assess this risk
factor.
Limitations
While this cross-sectional study is sufficiently powered to detect a difference in HPV preva-
lence compared to the estimate stated for Western Africa, it was not meant to be powered to
assess risk factors. The sociodemographic and behavioral characteristics are based on self-
reported questionnaires and may therefore be subject to biased answers. The associations we
found have to be investigated in larger studies and a similar context.
Additionally, problems with sample genotyping resulted in longer waiting times than
expected for the women participating. Since women may travel across the country with the
harvest season and also the CHWs responsible for the respective area change locations for
training, to mention only a few potential factors, only about half of the positively tested
women travelled to the clinic for follow-up. The unexpectedly high prevalence made it difficult
for all women to receive colposcopy and therefore the additional cytology triage step was intro-
duced. Therefore, we cannot make any conclusions on the clinical status of all women tested
positive and hence excluded the clinical outcome from any further analysis.
Conclusion
The main finding of this study is a higher prevalence of high risk HPV than expected until
now. Secondly, we found that three HPV types, namely HPV35, 56 and 59, are among the top
5 types found but not covered by any HPV vaccine even though they are found in 16.4% of cer-
vical cancers in Western Africa [31]. Thirdly, risk factors found for HPV positivity were young
age, the number of sexual partners and the relationship status.
Despite the high HPV prevalence found in the investigated population there is currently no
national screening program for cervical cancer screening in Ghana. Although the recent
national control program for non-communicable diseases (NCDs) states an instituted cervical
cancer screening system as a national policy priority, little of the suggested means have been
implemented until today [44] and the cervical cancer screening coverage remains low with
2.8% of women aged 25–64 years [45]. This is further highlighted by an analysis including cer-
vical cancer patients from the Catholic Hospital Battor in Ghana, showing that late presenta-
tion at the clinic was the main risk factor for cervical cancer diagnosis [5]. The high prevalence
of non-vaccine preventable HPV types shows the importance of secondary prevention efforts,
even if primary prevention with the available vaccines would be fully implemented. The results
of this study can therefore help in tailoring a screening system that is adapted to a higher than
expected HPV prevalence.
Self-sampling worked well and provided adequate samples for HPV-based screening. How-
ever, the high HPV prevalence found would require further triage and follow-up for a large
number of women, which can easily overburden the health system. This is a major aspect
when deciding on the feasible cervical cancer screening algorithm introduced on a wider scale.
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